Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Compugen Ltd. stock logo
CGEN
Compugen
$1.54
+2.0%
$1.60
$1.13
$2.66
$137.43M2.57422,260 shs74,666 shs
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$20.60
-0.7%
$18.61
$13.36
$32.27
$662.56M1.38314,766 shs85,595 shs
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
$16.94
+1.7%
$12.33
$6.71
$18.67
$741.97MN/A206,392 shs61,389 shs
VectivBio Holding AG stock logo
VECT
VectivBio
$16.85
$16.85
$4.25
$16.98
N/AN/AN/AN/A
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Compugen Ltd. stock logo
CGEN
Compugen
-1.95%-5.03%-7.93%+3.42%-17.03%
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
+1.67%+3.54%+23.09%-5.17%-21.91%
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
-6.30%+5.84%+49.02%+68.97%+1,665,999,900.00%
VectivBio Holding AG stock logo
VECT
VectivBio
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Compugen Ltd. stock logo
CGEN
Compugen
1.0876 of 5 stars
3.52.00.00.00.00.00.0
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
1.3645 of 5 stars
3.60.00.00.01.51.70.0
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
VectivBio Holding AG stock logo
VECT
VectivBio
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Compugen Ltd. stock logo
CGEN
Compugen
3.00
Buy$4.00164.90% Upside
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
3.13
Buy$53.00155.54% Upside
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
3.33
Buy$23.5041.06% Upside
VectivBio Holding AG stock logo
VECT
VectivBio
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CGEN, DNTH, MAZE, and VECT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$17.00
7/2/2025
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
5/13/2025
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$58.00 ➝ $50.00
5/13/2025
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Compugen Ltd. stock logo
CGEN
Compugen
$27.86M4.84N/AN/A$0.62 per share2.44
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$6.52M102.24N/AN/A$11.91 per share1.74
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
$167.50M4.36$0.14 per share116.14($7.11) per share-2.34
VectivBio Holding AG stock logo
VECT
VectivBio
$27.34MN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Compugen Ltd. stock logo
CGEN
Compugen
-$14.23M-$0.16N/AN/AN/A-51.27%-24.51%-12.19%8/5/2025 (Estimated)
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-$84.97M-$2.88N/AN/AN/A-1,544.23%-29.26%-27.87%8/6/2025 (Estimated)
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
$52.23MN/A0.00N/AN/AN/AN/AN/A
VectivBio Holding AG stock logo
VECT
VectivBio
-$93.74MN/A0.00N/AN/AN/AN/AN/A

Latest CGEN, DNTH, MAZE, and VECT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-$0.86N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Compugen Ltd. stock logo
CGEN
Compugen
-$0.07N/AN/AN/A$3.95 millionN/A
5/19/2025Q1 2025
Compugen Ltd. stock logo
CGEN
Compugen
-$0.06-$0.08-$0.02-$0.08$3.70 million$2.28 million
5/14/2025Q1 2025
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
-$0.76-$1.15-$0.39-$1.15N/AN/A
5/12/2025Q1 2025
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-$0.86-$0.82+$0.04-$0.82$0.81 million$1.16 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Compugen Ltd. stock logo
CGEN
Compugen
N/AN/AN/AN/AN/A
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
N/AN/AN/AN/AN/A
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
N/AN/AN/AN/AN/A
VectivBio Holding AG stock logo
VECT
VectivBio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Compugen Ltd. stock logo
CGEN
Compugen
N/A
5.09
5.09
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
N/A
15.98
15.99
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
N/A
16.10
16.10
VectivBio Holding AG stock logo
VECT
VectivBio
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Compugen Ltd. stock logo
CGEN
Compugen
12.22%
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
47.53%
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
N/A
VectivBio Holding AG stock logo
VECT
VectivBio
N/A

Insider Ownership

CompanyInsider Ownership
Compugen Ltd. stock logo
CGEN
Compugen
9.50%
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
8.15%
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
N/A
VectivBio Holding AG stock logo
VECT
VectivBio
9.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Compugen Ltd. stock logo
CGEN
Compugen
7089.24 million80.76 millionOptionable
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
8032.16 million26.83 millionOptionable
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
12143.80 millionN/AN/A
VectivBio Holding AG stock logo
VECT
VectivBio
30N/AN/ANo Data

Recent News About These Companies

A brain biotech launches with Roche’s spare parts
Etherio Group: 2024 CMI 25
Vicore Expands and Strengthens its Board of Directors
FDA approves DMD treatment from Italfarmaco
Only two sleeps left until February 31!

New MarketBeat Followers Over Time

Media Sentiment Over Time

Compugen stock logo

Compugen NASDAQ:CGEN

$1.54 +0.03 (+1.99%)
As of 01:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Dianthus Therapeutics stock logo

Dianthus Therapeutics NASDAQ:DNTH

$20.60 -0.14 (-0.67%)
As of 01:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Maze Therapeutics stock logo

Maze Therapeutics NASDAQ:MAZE

$16.94 +0.28 (+1.68%)
As of 01:29 PM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

VectivBio stock logo

VectivBio NASDAQ:VECT

$16.85 0.00 (0.00%)
As of 07/18/2025

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.